NextMeds Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 9.2/10
Best for: semaglutide at $79/month, 59% under the register median
What NextMeds does best is charge less than most of the register.
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
In the price
No insurance needed · Vetted by our editors
Membership is a single flat monthly charge, and inside it sit free shipping, a registered dietitian holding a license, a care coach working 1:1, telehealth visits and the drug itself where one is prescribed. Insurance is not billed. A free assessment online goes to a licensed provider, who adds a phone or video consult in states that demand one, then prescribes if it fits. Compounding pharmacies within the Next Meds network, all licensed, ship. Auto-renewal does not exist, cancellation is open, and all 50 states can order compounded tirzepatide and semaglutide.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to NextMeds
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
NextMeds at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $79/mo (Compounded Semaglutide Membership, drug included when prescribed, alongside telehealth visits, a care coach, a dietit...)
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Medication · Consult · Shipping · Coaching
- Availability
- All 50 states
- FDA status
- No FDA warning letter on record
How NextMeds scores
Six columns, each one computed from something NextMeds has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
10.0/10$109/month is 59% below the register median of $267 for compounded tirzepatide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
7.5/10does not name a dispensing pharmacy; shows a price before asking for health information; publishes its state list. Our verification confidence is medium.
Accessibility10%
10.0/10Publishes coverage in 50 of 50 states.
Support10%
8.5/10The price covers medication, consult, shipping, coaching.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on NextMeds
Last checked August 2026- Re-read the price on file across 2 dose or plan tiers
- Checked state coverage: all 50
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with NextMeds involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1NextMeds publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3NextMeds does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, shipping, coaching.
- Cheapest standing monthly prices on record: semaglutide $79, tirzepatide $109. Membership fees, first-month rates and insured copays are excluded from those figures.
- Coverage is published for all 50 states.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
NextMeds support, as documented
- care@nextmeds.com
GLP-1 medications NextMeds offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Compounded Semaglutide Membership, drug included when prescribed, alongside telehealth visits, a care coach, a dietitian and shipping. $79 is the month-to-month rate read from the pricing section on 2026-08-14. The site headline reads 'from $49/mo': that is the 12-month prepaid term divided down, not a monthly price, and the ladder between them is 3-month $76, 6-month $73, 12-month $49. A summer promotion was running with a stated end of August 20, so $79 may itself be discounted.
Compounded Tirzepatide Membership, drug included when prescribed, alongside telehealth visits, a care coach, a dietitian and shipping. $109 is the month-to-month rate read from the pricing section on 2026-08-14. The advertised 'GLP-1 + GIP: $95' is the 12-month prepaid term divided down; the ladder is 3-month $105, 6-month $100, 12-month $95. A summer promotion was running with a stated end of August 20, so $109 may itself be discounted.
Check the price yourself before you pay
Every figure here was read off NextMeds's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide at $79 a month, 58% below the $189 median for the same drug and form across this register
- Tirzepatide at $109 a month, 59% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping, coaching
- Coverage is published for all 50 states
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What NextMeds charges
NextMeds charges $79/month, and holds that rate across every dose. That sits at the affordable end of what we track. Flat dose pricing matters more than it reads: on a tiered plan the bill grows as the dose does, which means the figure that persuaded you to sign up is not the figure you end up living with.
- Compounded semaglutide — $79/month
- Compounded tirzepatide — $109/month
Across the GLP-1 providers in our register the median standing price is about $169/month, so NextMeds is genuinely under the middle rather than merely advertising that it is.
Ivim Health dispenses semaglutide and tirzepatide from $75/month, which makes it the honest comparison to run before committing here.
What NextMeds dispenses
NextMeds prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two molecules with the largest published weight-loss trial programs behind them. What arrives is compounded at a licensed pharmacy, not an approved pen. That is the reason it costs less, and the reason the finished preparation carries no FDA review behind it.
What we could verify
On the record: it treats patients in all 50 states and coaching is included rather than sold on top. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- the lowest standing monthly cost is what you are solving for
- you want the price to stop moving as your dose climbs
- you want coaching bundled rather than metered
- you need access regardless of where you live
Our read
NextMeds competes on price and does it without an obvious sacrifice elsewhere: $79/month, no warning letter on file, and access that is not unusually restricted.
The Bottom Line
What NextMeds does best is charge less than most of the register.
Before you pay NextMeds
Starting at $79/month. Check today's price, then book the free consultation.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this NextMeds review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See NextMeds's current pricing
Plans start at $79/month. The free consultation is where you learn whether you qualify, and what it costs today.